InvestorsHub Logo
Followers 1321
Posts 26906
Boards Moderated 6
Alias Born 12/10/2012

Re: None

Thursday, 04/13/2017 9:15:28 AM

Thursday, April 13, 2017 9:15:28 AM

Post# of 512
$RLMD: Double-Bottom, Bull-Flag... Boomage. FASTTRACK FDA!!!!!

Flyer ALERT here.


**************************************************************


Relmada Therapeutics announces that the FDA has granted Fast Track designation for d-Methadone for the adjunctive treatment of major depressive disorder

Font size: A | A | A

8:02 AM ET 4/13/17 | Briefing.com

Relmada is planning to advance the development program for REL-1017 to a phase 2a randomized, double-blind, placebo-controlled study in patients with major depressive disorder. The study will assess changes in depressive symptoms as well as the safety, tolerability and pharmacokinetics of two dose levels of REL-1017 as rapid acting adjunctive treatment in patients during a seven-day dosing period and 14-day observation period.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RLMD News